ArticleJournal of global oncology2017

PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That Progressed on Prior Endocrine Therapy-Safety and Efficacy in Asian Patients.

Hiroji Iwata et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.